The drug, Iovance Biotherapeutics’ Amtagvi, is a tumor-derived autologous T cell immunotherapy that expands a patient’s own T cells to fight the cancer.
The medicine is indicated for unresectable or metastatic melanoma, which is when the cancer cannot be removed surgically or spreads to other body parts. Melanoma is a rare form of skin cancer that accounts for a significant number of cancer-related deaths, the FDA said.
Amtagvi (lifileucel) is the first approved drug for treating solid tumor cancer, Iovance said in a news release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
